• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

FDA Oks skin cancer drug

Article

Rockville, Md. - The U.S. Food and Drug Administration has approved Zolinza (vorinostat, Merck) capsules for treatment of refractory cutaneous T-cell lymphoma (CTCL).

Rockville, Md. - The U.S. Food and Drug Administration has approved Zolinza (vorinostat, Merck) capsules for treatment of refractory cutaneous T-cell lymphoma (CTCL).

Researchers at M.D. Anderson Cancer Center, Houston, evaluated doses and schedules of Zolinza in 33 patients with CTCL who had received a median of five prior regimens. Partial responses occurred in eight of 33 patients, with 14 of 31 evaluable patients having relief of pruritis. The median time to treatment response was 12 months, the duration of response was 15 months and time to tumor progression was 30 months.

Recent Videos
Andrew Alexis, MD, MPH, an expert on vitiligo
Andrew Alexis, MD, MPH, an expert on vitiligo
Andrew Alexis, MD, MPH, an expert on vitiligo
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
This series features 1 KOL.
This series features 1 KOL.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
Latanya Benjamin, MD, FAAD, FAAP, an expert on vitiligo
© 2024 MJH Life Sciences

All rights reserved.